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A phase 1 dose-escalation and expansion
study of binimetinib (MEK162), a potent and
selective oral MEK1/2 inhibitor
Johanna C Bendell*,1, Milind Javle2, Tanios S Bekaii-Saab3, Richard S Finn4, Zev A Wainberg4, Daniel A Laheru5,
Colin D Weekes6, Benjamin R Tan7, Gazala N Khan8, Mark M Zalupski9, Jeffrey R Infante1, Suzanne Jones10,
Kyriakos P Papadopoulos11, Anthony W Tolcher11, Renae E Chavira12, Janna L Christy-Bittel12,13, Emma Barrett12,13
and Amita Patnaik11
Background: Binimetinib (MEK162; ARRY-438162) is a potent and selective oral MEK 1/2 inhibitor. This phase 1 study determined
the maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and preliminary anti-tumour activity
of binimetinib in patients with advanced solid tumours, with expansion cohorts of patients with biliary cancer or KRAS- or BRAFmutant colorectal cancer.
Methods: Binimetinib was administered twice daily. Expansion cohorts were enroled after MTD determination following a 3 þ 3
dose-escalation design. Pharmacokinetic properties were determined from plasma samples. Tumour samples were assessed for
mutations in RAS, RAF, and other relevant genes. Pharmacodynamic properties were evaluated in serum and skin punch biopsy
samples.
Results: Ninety-three patients received binimetinib (dose-escalation phase, 19; expansion, 74). The MTD was 60 mg twice daily,
with dose-limiting adverse events (AEs) of dermatitis acneiform and chorioretinopathy. The dose for expansion patients was
subsequently decreased to 45 mg twice daily because of the frequency of treatment-related ocular toxicity at the MTD. Common
AEs across all dose levels included rash (81%), nausea (56%), vomiting (52%), diarrhoea (51%), peripheral oedema (46%), and
fatigue (43%); most were grade 1/2. Dose-proportional increases in binimetinib exposure were observed and target inhibition was
demonstrated in serum and skin punch biopsy samples. Three patients with biliary cancer had objective responses (one complete
and two partial).
Conclusions: Binimetinib demonstrated a manageable safety profile, target inhibition, and dose-proportional exposure. The
45 mg twice daily dose was identified as the recommended phase 2 dose. The three objective responses in biliary cancer patients
are encouraging and support further evaluation in this population.

Growth factor-mediated proliferative signals are transmitted from
the extracellular environment to the nucleus through several
pathways, including the mitogen-activated protein kinase (MAPK)
pathway (Chang et al, 2003b; Schulze et al, 2004; Roberts and Der,
2007). Activation of this pathway results in a signal cascade leading
to sequential phosphorylation and activation of MAPK kinase
(MEK) and extracellular signal-regulated kinase (ERK). Activated
ERK regulates gene expression through phosphorylation of a
variety of transcription factors that control key cellular activities,

including proliferation, differentiation, migration, survival, and
angiogenesis. Aberrant signalling through this pathway has been
shown to lead to unconstrained cell growth and cell transformation
(Scholl et al, 2005; Yoon and Seger, 2006), and is characteristic of
many cancers.
Inappropriate MAPK pathway activation can occur through
several distinct mechanisms, including activating mutations in RAS
and BRAF (Bos, 1989; Davies et al, 2002; Lea et al, 2007), activated
growth factor signalling (Bennasroune et al, 2004; Nakazawa et al,
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2005), and cytokines and stress response signals (McCubrey et al,
2000; Chang et al, 2003a). In addition to potential cytokine
involvement in tumorigenesis, increased cytokine levels may
contribute to conditions such as fatigue, cachexia, and depression
in patients with cancer (Reyes-Gibby et al, 2008). Collectively,
these data suggest that targeting the MAPK pathway via MEK
inhibition may inhibit cancer signalling mediated by a wide variety
of signals.
Mitogen-activated protein kinase pathway activation is observed
in many cancer types, including biliary and colorectal cancers (The
Wellcome Trust Sanger Institute). In biliary cancer, activation
appears to involve a number of events as follows: mutations in RAS
or BRAF (Tannapfel et al, 2000; Tannapfel et al, 2003); aberrant
activation of growth factor receptors such as ERBB family member
epidermal growth factor receptor and ERBB2, and cellular
mesenchymal–epithelial transition factor receptor (Aishima et al,
2002; Nakazawa et al, 2005); and stimulation of interleukin (IL)-6
(Park et al, 1999a; Park et al, 1999b). The MEK inhibitor
selumetinib (AZD6244; ARRY-142886) has shown promising
clinical activity as monotherapy (Bekaii-Saab et al, 2011), and is
being tested in combination with cisplatin and gemcitabine
(Bridgewater et al, 2016; NCT02151084), in patients with biliary
cancer. Furthermore, activating mutations in KRAS or BRAF occur
in approximately 50%–60% of patients with colorectal cancer; these
mutations are mutually exclusive and are associated with resistance
or decreased response to anti-epidermal growth factor receptor
therapy in colorectal cancer (Davies et al, 2002; Fransen et al, 2004;
Karapetis et al, 2008). Therefore, targeting MEK represents a
compelling strategy for treating these diseases.
Binimetinib (MEK162; ARRY-438162) is a potent, adenosine
triphosphate-uncompetitive, highly selective allosteric inhibitor of
MEK1/2 with demonstrated on-target activity in vitro and in vivo,
including models of cancer (Lee et al, 2010; Woessner et al, 2010).
Binimetinib has nanomolar activity against purified MEK enzyme
(half-maximal inhibitory concentration, 12 nM) and markedly
inhibits ERK phosphorylation in human cell lines. Binimetinib
potently inhibits the proliferation of a subset of cells in panels of
human cancer cell lines and is particularly active in cells
harbouring activating mutations in the BRAF, NRAS, and KRAS
genes (Lee et al, 2010). In vivo, binimetinib displays broad antitumour activity in xenograft models derived from melanoma,
colorectal cancer, non-small cell lung cancer (NSCLC), fibrosarcoma, cholangiocarcinoma, and pancreatic cancer. These nonclinical data support the use of binimetinib in a wide variety of
tumour types, with a priority in tumours with aberrantly activated
MAPK pathway signalling.
The primary objectives of this phase 1 study were to determine
the maximum tolerated dose (MTD) of binimetinib and characterise its safety and pharmacokinetic profiles. Secondary
objectives included characterisation of the pharmacodynamic
profile and anti-tumour activity. Following the MTD determination, three expansion cohorts of patients with biliary cancer, KRASmutant colorectal cancer, and BRAF-mutant colorectal cancer
were enroled to further assess the safety and clinical activity of
binimetinib.
MATERIALS AND METHODS

This study (NCT00959127) was conducted under all applicable
regulatory requirements. The study was approved by the institutional review boards of all participating sites, and patients provided
written informed consent before the initiation of study-related
treatment or procedures.
Study design and treatment. This multicentre, open-label, phase 1
study comprised two phases: a dose-escalation phase and an
576
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expansion phase. In the dose-escalation phase, a modified 3 þ 3
design was employed to determine the MTD of binimetinib
administered orally twice daily (BID) in a 21-day treatment cycles.
A single dose of binimetinib was administered on day 1 and then BID
continuously beginning on day 2 of cycle 1. A starting dose
of 30 mg BID was utilised for the dose-escalation phase. The
dose was escalated in cohorts of at least three evaluable patients at
45 mg BID, 60 mg BID, and 80 mg BID until MTD was determined.
Patients in the expansion phase received continuous BID treatment
with binimetinib beginning on day 1 of cycle 1 at the MTD
determined in the dose-escalation phase. Patients were instructed to
take BID doses 12±2 h apart with water, irrespective of food.
Patients were evaluable for dose-escalation decisions if they
received at least 80% of the assigned doses or had a dose reduction,
interruption, or discontinuation due to binimetinib-related toxicities during the first 21-day treatment cycle. Dose-limiting
toxicities (DLTs) were any adverse event (AE) not clearly
attributable to the patient’s disease, including haematologic
toxicities of grade 4 neutropenia for X5 days, febrile neutropenia,
grade 4 thrombocytopenia, and grade 3 thrombocytopenia with
bleeding. Any grade 3 or 4 non-haematologic adverse events (AEs),
including grade 3 nausea, vomiting, diarrhoea, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevations
47  the upper limit of normal (ULN) in patients with liver
metastases and AST/ALT 2.5 to 5  ULN at baseline, or rash
despite maximal supportive care, were also considered dose
limiting with the exception of isolated grade 3 or 4 elevations in
troponin, brain natriuretic peptide (BNP), prohormone BNP, or
atrial natriuretic peptide levels, unless these were associated with
cardiac symptoms. Patients who required dosing interruption 421
days for drug-related AEs were classified as having experienced
DLT, unless the interruption was due to grade 1/2 rash. The MTD
was defined as the dose level below the dose that resulted in DLTs
in X33% of patients.
Patient selection. To be eligible for any phase of this study,
patients X18 years of age were required to have a cardiac ejection
fraction greater than or equal to the institutional lower limit of
normal by echocardiogram or multigated acquisition (MUGA)
scan and adequate bone marrow, renal, and hepatic function.
The dose-escalation phase included patients with advanced solid
tumours refractory to standard treatment, those who had no
standard therapy available or chose not to pursue standard therapy,
and those with an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, with either measurable or evaluable
disease, who were willing to undergo skin punch biopsy sampling.
Patients with a history of central serous retinopathy (CSR),
baseline risk factors for CSR, or retinal vein occlusion, and those
who received previous MEK inhibitor treatment were excluded
from the expansion phase. To be eligible for the biliary cancer
expansion cohort, patients were required to have histologically or
cytologically confirmed intra-hepatic or extra-hepatic cholangiocarcinoma or gallbladder carcinoma that was unresectable, locally
advanced, or metastatic, and to have received no more than one
prior anti-cancer therapy (including adjuvant therapy), an ECOG
performance status 0 or 1, and either measurable or evaluable
disease. Patients in the colorectal cancer expansion cohorts were
required to have documented KRAS- or BRAF-mutant metastatic
colorectal adenocarcinoma, histologically or cytologically confirmed, and to have previously received or were ineligible for
5-fluorouracil, oxaliplatin, irinotecan, and/or bevacizumab. These
patients were further required to have ECOG performance status of
0 to 2 measurable disease and be willing to undergo skin punch
biopsy sampling. Patients in all expansion cohorts were required to
submit archival tissue or undergo a fresh biopsy for pharmacodynamic analysis.
www.bjcancer.com | DOI:10.1038/bjc.2017.10
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Safety assessments. All patients underwent a complete medical
history and physical examination, assessment of ECOG performance status and vital signs, and laboratory analysis of
haematology, coagulation, clinical chemistry, and urine. Three
serial resting and supine 12-lead electrocardiograms were conducted over 5–10 min and cardiac ejection fraction was assessed by
echocardiogram or MUGA. In addition, a complete ophthalmologic examination (including visual acuity; fundoscopy and
tonometry; optical coherence tomography; and slit-lamp, lens,
vitreous, and fluorescence dye examinations) was performed on
each patient. These assessments were repeated throughout study
participation and/or as clinically indicated. Adverse events were
reviewed on an ongoing basis.
Efficacy assessments. Efficacy was assessed through radiologic
scans and clinical measurements of disease sites (if applicable), and
evaluation of serologic tumour markers in patient blood samples as
appropriate for tumour type. Tumour assessments were performed
within 21 days before the first dose and then every 6 weeks starting
at the end of cycle 2. Tumour response was evaluated by the
investigator using Response Evaluation Criteria in Solid Tumours
(RECIST) version 1.1 criteria. Tumour marker levels were
incorporated into the overall response assessment per RECIST.
Pharmacokinetic analysis. Blood for plasma binimetinib and
metabolite concentration assessments was collected on cycle 1 day
1 (pre-dose and 30 min to 24 h post dose), cycle 1 day 15 (pre-dose
and 30 min to 8 h post dose), and cycles 2 to 8 day 1 (pre-dose)
from patients in the dose-escalation phase and from selected
patients in the biliary cancer cohort of the expansion phase
(intensive pharmacokinetic sampling). The remaining patients in
the expansion phase underwent limited pharmacokinetic sampling
on cycle 1 day 1 (pre-dose), cycle 1 day 8 (pre-dose), cycle 1 day 15
(pre-dose and 30 min to 8 h post dose), cycle 2 day 1 (pre-dose),
cycle 3 day 1 (pre-dose and 30 min to 8 h post dose), and cycles 4–8
day 1 (pre-dose). Standard non-compartmental pharmacokinetic
parameters were calculated on serial pharmacokinetic collection
days (cycle 1 day 1 and cycle 1 day 15 for the dose-escalation
phase; cycle 1 day 15 and cycle 3 day 1 for the expansion phase) for
each patient and summarised by cohort. Dose proportionality,
accumulation, and metabolite-to-parent ratio were assessed as
appropriate.
Pharmacodynamic analysis. All patients had venous blood
samples collected pre-dose at baseline, cycle 1 day 1 (only if 2
samples were not collected at baseline), cycle 1 day 8, cycle 1 day
15, and day 1 of all subsequent cycles for measurement of serum
tumour necrosis factor (TNF)-a levels. A sample was also collected
at 2–4 h post dose from patients in the colorectal cancer expansion
cohorts. Tumour necrosis factor-a was measured by a multiplexed
electro-chemiluminescence assay.
Tumour samples for mutational analysis were optional in the
dose-escalation phase and required in the expansion phase cohorts.
Mutational analysis of KRAS, NRAS, BRAF, and PI3KCa was
performed using the Sequenom OncoCarta Panel (Sequenom, San
Diego, CA) and/or BEAMing digital PCR (Inostics GmbH,
Hamburg, Germany) and results were reported as mutated or
wild type. Phosphatase and tensin homolog (PTEN) expression
was determined by immunohistochemistry using PTEN mouse
monoclonal antibody (clone 6H2.1; Dako, Carpinteria, CA),
visualised with 3,30 -diaminobenzidine (DAB) and counterstained
with haematoxylin. Phosphatase and tensin homolog expression
was reported as an H-score and classified as PTEN null (Hscoreo50) or PTEN positive (H-scoreX50). The absence of PTEN
expression (PTEN null) indicated a PTEN mutation.
Skin punch biopsies (with hair follicles, if feasible) were
obtained from patients in the dose-escalation phase and colorectal
cancer expansion phase cohorts pre-dose at baseline and post dose
www.bjcancer.com | DOI:10.1038/bjc.2017.10
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within 7 days of cycle 1 day 15 for measurement of Ki67 and pERK
expression. Ki67 and pERK expression were determined by
immunohistochemistry using a Ki67 rabbit monoclonal antibody
(clone 30-9; Ventana Medical Systems, Inc., Tucson, AZ, USA) and
a pERK rabbit monoclonal antibody (Thr202/Tyr204, clone 20G11;
Cell Signaling Technology, Inc., Danvers, MA), respectively,
visualised with DAB and counterstained with haematoxylin. Ki67
was expressed as percentage of tumour cells with positive stain;
pERK was expressed as an H-score.
Statistical methodology. This study tested no formal hypotheses,
and analyses were descriptive. The dose-escalation phase utilised a
modified 3 þ 3 design. This modified design allowed three or four
evaluable patients to be enroled in a cohort, with expansion up to a
total of six evaluable patients if a DLT was observed. A DLT rate of
X33% was considered unacceptable. It was estimated that a total of
30 patients would be treated in the dose-escalation phase.
Expansion phase cohorts were planned to enrol up to 65 patients
(25 patients with biliary cancer, 25 patients with KRAS-mutant
colorectal cancer, and 15 patients with BRAF-mutant colorectal
cancer) to further describe the tolerability at the MTD and to
obtain preliminary estimates of anti-tumour activity. For an
observed DLT rate of 33%, an expansion cohort of 25 patients
would enable a 95% confidence interval (CI) range of 15% to 54%,
and for an observed response rate of 12%, 25 patients would result
in a 95% CI ranging from 3% to 31%. A Bayesian rule to monitor
toxicity was employed in the expansion phase.
Adverse events and serious AEs (SAEs) were coded by preferred
term (PT) and system organ class using the Medical Dictionary for
Regulatory Activities version 12.0. The severity of AEs was assessed
by investigators using the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0. Two AEs of
special interest were captured under the composite terms of
‘combined rash’ and ‘combined ocular events.’ The ‘combined rash’
term included the PTs of dermatitis acneiform, acne, skin
exfoliation, and any term containing ‘rash’. The ‘combined ocular
events’ term included the PTs of retinal deposits, retinopathy,
papilloedema, chorioretinopathy, macular oedema, retinal detachment, and retinal disorder.
All patients who received X1 dose of binimetinib were included
in the safety analysis. Patients in the safety analysis who had X1
measurable lesion at baseline and at least 1 post-baseline disease
assessment were evaluable for efficacy. Kaplan–Meier estimates of
progression-free survival (PFS) and overall survival (OS) were
performed for patients in the expansion phase (Kaplan and Meier,
1958) using SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS

Between August 2009 and May 2012, a total of 93 patients (median
age, 58 years; 61% men) were enroled at 9 clinical sites in the
United States. Patient characteristics are outlined in Table 1.
Nineteen patients were enroled in the dose-escalation phase, with
an additional 74 patients treated in the expansion phase. The
expansion cohort included 28 patients with biliary cancer (60 mg
BID dose group), 31 patients with KRAS-mutant colorectal cancer
(6 patients in the 60 mg BID dose group and 25 in the 45 mg BID
dose group), and 15 patients with BRAF-mutant colorectal cancer
(45 mg BID dose group).The predominant tumour type was
colorectal (57%); 54% of patients had an ECOG performance
status of 0.
Dose escalation, DLTs, and MTD. Cohorts of four patients each
(three of whom were evaluable for dose-escalation decisions in
each cohort) were treated at 30 and 45 mg BID without evidence of
DLTs. At the 60 mg BID dose level, one patient experienced grade
2 retinopathy; although this was not considered a DLT, this cohort
577
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was expanded to six evaluable patients with no DLTs noted.
Enrolment proceeded to 80 mg BID; four patients were enroled,
three of whom were evaluable. The MTD was then exceeded at
80 mg BID, with two of the three evaluable patients experiencing
DLTs of grade 3 chorioretinopathy and grade 3 dermatitis
acneiform. Both DLTs resolved with study drug interruption and
both patients resumed study drug with a dose reduction. The
60 mg BID dose was declared the MTD and was the starting dose
in the expansion phase. However, after initiating the expansion
phase, a higher-than-expected incidence of ocular toxicities at
60 mg BID precluded treatment of patients continuously at this
dose. The starting dose was therefore reduced to 45 mg BID for
newly enroled expansion phase patients.

Table 1. Patient characteristics

Safety and tolerability. Adverse events (regardless of causality)
are shown in Table 2. Common AEs (all grades) included
combined rash, nausea, vomiting, diarrhoea, peripheral oedema,
and fatigue. Ocular events were reported in 19% of patients. Most
patients experienced grade 2 (41%) or grade 3 (49%) events. The
most common grade 3 events included anaemia (11%), and
abdominal pain and dehydration (4% each). Grade 4 AEs were
reported for 6% of patients; those that occurred in at least two
patients included anaemia (3%). There were no grade 5 events.
Laboratory abnormalities included increases in creatine phosphokinase (CK) and liver function tests.
Adverse events that resulted in dose reduction were reported for
16%, 49%, and 75% of patients in the 45 mg BID, 60 mg BID, and
80 mg BID dose groups, respectively. Dose reductions were most
commonly due to chorioretinopathy (9%); photopsia, combined
rash, and retinal detachment (3% each); and diarrhoea, fatigue,
increased CK, macular oedema, myodesopsia, retinopathy, visual
impairment, and vomiting (2% each).
Adverse events resulting in treatment discontinuation occurred
in 16%, 15%, and 25% of patients in the 45 mg BID, 60 mg BID,
and 80 mg BID dose groups, respectively. Adverse events resulting
in discontinuation were most commonly due to fatigue and nausea
(3% each), and combined rash and small intestinal obstruction
(2% each).
Twenty-eight patients (30%) reported SAEs during the study or
within 30 days of the last binimetinib dose; SAEs were reported for
50%, 20%, and 41% of patients in the 30 mg BID, 45 mg BID, and
60 mg BID dose groups, respectively. SAEs that occurred in at least
two patients included anaemia (4%) and bacteraemia, dehydration,
gastrointestinal haemorrhage, pneumonia, small intestinal obstruction, and ulcer haemorrhage (2% each). The maximum reported
SAE severity was grade 2 for 5% of patients, grade 3 for 22%, and
grade 4 for 3%. Grade 4 SAEs included anaemia and pulmonary
embolism (1 patient in the 60 mg BID dose group), generalised
oedema (1 patient in the 60 mg BID dose group), and cytoreductive
surgery (1 patient in the 45 mg BID dose group).
Twenty patients (22%) died during the study or within 30 days
of the last binimetinib dose. The cause of death for all of these
patients was disease progression.

Colorectal
Biliary
Pancreas
Othera

Adverse events of special interest. Known class effects of MEK
inhibitors, such as rash, ocular events, gastrointestinal events,
increased CK, and oedema, were considered AEs of special interest
and analysed in greater detail.
Rashes and related skin disorders were reported for 81% of
patients. The incidence (77% and 88%) and median time to onset
(8 days and 10 days) of combined rash were relatively similar
between patients in the 45 mg BID and 60 mg BID dose groups,
respectively. Combined rash was primarily grade 1 (44% of
patients) or grade 2 (33% of patients), generally did not require
dose modifications, and was frequently treated with concomitant
medications. Three patients (3%) had grade 3 combined rash that
required either dose modification (interruption and/or reduction)
or treatment discontinuation.
578

Characteristic

N ¼ 93

Median age, years (range)

58 (30–86)

Sex, n (%)
Men
Women

57 (61)
36 (39)

Race, n (%)
White
Black/African American
Asian
Other

80
7
3
3

(86)
(8)
(3)
(3)

53
30
3
7

(57)
(32)
(3)
(8)

Tumour type, n (%)

ECOG performance status, n (%)
0
1
2

50 (54)
42 (45)
1 (1)

Median prior regimens for advanced/metastatic disease (range)

2 (0–10)

b

Prior treatments, n (%)
Radiation
Surgery
Adjuvant therapy

30 (32)
73 (78)
48 (52)

Enrolment, n (%)
Dose-escalation phase
30 mg BID
45 mg BID
60 mg BID
80 mg BID
Expansion phasec
Biliary cancer cohort (60 mg BID)
KRAS-mutant colorectal cancer cohort (60 mg BID)
KRAS-mutant colorectal cancer cohort (45 mg BID)
BRAF-mutant colorectal cancer cohort (45 mg BID)

19
4
4
7
4
74
28
6
25
15

(20)
(4)
(4)
(8)
(4)
(80)
(30)
(6)
(27)
(16)

Abbreviations: BID ¼ twice daily; ECOG ¼ Eastern Cooperative Oncology Group; MTD ¼
maximum tolerated dose.
a
Includes appendiceal, carcinoma of unknown primary, eccrine adenocarcinoma, gastric,
melanoma, nerve sheath tumour, and parotid.
b
Patients may have received more than 1 prior cancer treatment.
c

After initiating the expansion phase, a higher-than-expected incidence of ocular AEs
affected the ability to treat patients continuously at the MTD of 60 mg BID. The dose was
therefore reduced to 45 mg BID for the remainder of newly enroled expansion phase
patients.

Combined ocular events were considered related to binimetinib
and were reported for 19% of patients. The incidence of ocular
events was higher with increasing binimetinib dose (0%, 11%, 27%,
and 50% of patients in the 30 mg BID, 45 mg BID, 60 mg BID, and
80 mg BID dose groups, respectively). Of the 18 patients with
ocular events, the median time to onset after the initiation of
binimetinib treatment was 17 days (range, 2–168 days). Abnormal
retinal findings were observed using fundoscopy and/or optical
coherence tomography. The objective findings were generally
reported as macular oedema, CSR, sub-retinal fluid, or serous
detachments of the retina. Ocular events were primarily grade 1
(5% of patients) or grade 2 (13% of patients) and were managed
mainly with dose modifications, including brief dose interruptions
and/or reductions. Ocular events were reversible in most patients
upon dose reduction or discontinuation of binimetinib; 78% of
patients had complete resolution, 17% were reported as recovering/
resolving with retinal images documenting improvement, and 6%
of patients had stable retinal findings at the time of treatment
discontinuation for disease progression. One patient (1%) had a
grade 3 ocular event of chorioretinopathy that was managed with a
www.bjcancer.com | DOI:10.1038/bjc.2017.10
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Table 2. Adverse events, regardless of causality, reported in X15% of patients, all grades by dose level (N ¼ 93)
30 mg BID (n ¼ 4)

45 mg BID (n ¼ 44)

60 mg BID (n ¼ 41)

80 mg BID (n ¼ 4)

Adverse event, n (%)

Gr 1/2

Gr 3/4

Gr 1/2

Gr 3/4

Gr 1/2

Gr 3/4

Gr 1/2

Combined rasha

4 (100)

0 (0)

33 (75)

1 (2)

35 (85)

1 (2)

0 (0)

Gr 3/4 Total (N ¼ 93)
1 (25)

75 (81)

Nausea

3 (75)

0 (0)

27 (61)

0 (0)

21 (51)

0 (0)

1 (25)

0 (0)

52 (56)

Vomiting

3 (75)

0 (0)

23 (52)

0 (0)

20 (49)

0 (0)

2 (50)

0 (0)

48 (52)

Diarrhoea

4 (100)

0 (0)

17 (39)

0 (0)

25 (61)

0 (0)

1 (25)

0 (0)

47 (51)

Peripheral oedema

0 (0)

0 (0)

20 (45)

0 (0)

21 (51)

0 (0)

2 (50)

0 (0)

43 (46)

Fatigue

2 (50)

0 (0)

18 (41)

2 (5)

16 (39)

1 (2)

1 (25)

0 (0)

40 (43)

Anaemia

1 (25)

0 (0)

5 (11)

3 (7)

5 (12)

10 (24)

0 (0)

0 (0)

24 (26)

Abdominal pain

1 (25)

0 (0)

7 (16)

1 (2)

7 (17)

3 (7)

1 (25)

0 (0)

20 (22)

Anorexia

1 (25)

0 (0)

8 (18)

0 (0)

8 (20)

0 (0)

1 (25)

0 (0)

18 (19)

Combined ocular eventsb

0 (0)

0 (0)

5 (11)

0 (0)

11 (27)

0 (0)

1 (25)

1 (25)

18 (19)

Constipation

2 (50)

0 (0)

6 (14)

0 (0)

8 (20)

2 (5)

0 (0)

0 (0)

18 (19)

Dyspnoea

2 (50)

0 (0)

5 (11)

2 (5)

6 (15)

1 (2)

1 (25)

0 (0)

17 (18)

Pyrexia

2 (50)

0 (0)

7 (16)

0 (0)

7 (17)

1 (2)

0 (0)

0 (0)

17 (18)

Dizziness

0 (0)

0 (0)

5 (11)

0 (0)

9 (22)

0 (0)

0 (0)

0 (0)

14 (15)

Abbreviations: BID ¼ twice daily; Gr ¼ grade; PT ¼ preferred term.
a
Combined rash term includes PTs of dermatitis acneiform, acne, skin exfoliation, and any term containing rash.
b
Combined ocular events term includes PTs of retinal deposits, retinopathy, papilloedema, chorioretinopathy, macular oedema, retinal detachment, and retinal disorder.

dose reduction and concomitant medications. Vascular eye events
were included in the combined ocular events term; one grade 1
event of venous stasis retinopathy was reported in 1 patient (1%),
which was considered related to binimetinib and led to permanent
discontinuation of treatment.
Gastrointestinal events of nausea, vomiting, and diarrhoea were
reported for 56%, 52%, and 51% of patients, in the 30 mg BID,
45 mg BID, and 60 mg BID dose groups, respectively. In the
45 mg BID and 60 mg BID dose groups, the incidences of nausea
(61% and 51% of patients, respectively) and vomiting (52%
and 49% of patients, respectively) were similar, whereas the
incidence of diarrhoea was higher in the 60 mg BID dose group
(61% of patients) compared with the 45 mg BID dose group (39%
of patients). The maximum reported severity of nausea, vomiting,
or diarrhoea was either grade 1 or grade 2. Gastrointestinal events
were managed mainly with concomitant medications; however,
some events required dose modifications. Three patients (3%) were
permanently discontinued from treatment for nausea; none were
discontinued for vomiting or diarrhoea.
Increased CK was reported for 69% of patients; 10% of patients
had clinically significant CK values (i.e., values that shifted by X3
grades from baseline and/or were grade 4). Abnormal CK values
were reported as AEs of increased blood CK (13% of patients) and
increased blood CK-MB (1% of patients), and all were considered
to be related to binimetinib. Most instances of increased CK were
asymptomatic. Four patients (4%) required a dose modification
for AEs of increased blood CK; no patients were permanently
discontinued from treatment. Most patients with elevated CK had
B90% to 100% CK-MM.
Peripheral oedema was reported for 46% of patients. The
incidences were similar in the 45 mg BID, 60 mg BID, and 80 mg
BID dose groups (45%, 51%, and 50% of patients, respectively).
The maximum reported severity of peripheral oedema was either
grade 1 (32% of patients) or grade 2 (14% of patients) and was
managed mainly with concomitant medications. One patient (1%)
was permanently discontinued from treatment for two events of
treatment-related grade 1 peripheral oedema.
Pharmacokinetics. The geometric mean plasma binimetinib
concentration-time profiles on cycle 1 day 15 for intensive and
www.bjcancer.com | DOI:10.1038/bjc.2017.10

limited pharmacokinetic sampling are shown in Figure 1 and
Figure 2, respectively. Binimetinib was approximately dose
proportional over the dose range tested on days 1 and 15 of cycle
1. In the intensive pharmacokinetic sampling, the pre-dose
concentrations on cycle 1 day 15 were up to threefold higher than
the 12 h concentrations on day 1 and the accumulation ratios in the
dose-escalation phase cohorts were 1.50 (45 mg BID cohort) and
1.17 (60 mg BID cohort), indicating moderate accumulation
(Table 3). Although a formal steady-state analysis was not
conducted, in the limited pharmacokinetic sampling scheme, the
pre-dose concentrations were similar on cycle 1 day 15 and cycle 3
day 1 for the 45 mg BID dose group and the 60 mg BID dose group,
indicating that equilibrium was reached and binimetinib was likely
at steady state by cycle 1 day 15. Time of first maximum observed
plasma concentration (tmax) was similar, with median values of 0.5
to 4 h across all dose levels and both sampling schemes (noting the
limited sampling schedule did not have samples between 1.5 and
4 h, biasing the median tmax in those cohorts). The metabolite
exposure was o23% of binimetinib across dose levels.
Pharmacodynamics and tumour tissue analysis. Pharmacodynamic blood samples for serum concentrations of TNF-a were
collected from 78 patients. Median decreases of TNF-a ranging
from 33% to 49% of baseline were observed at all time points
across the 30 mg BID to 80 mg BID dose range, with no dosedependent trend observed. There were no notable changes in
C-reactive protein, interferon, IL-10, IL-12p70, IL-1b, IL-6, or IL-8.
Skin expression of Ki67, pERK, and pMEK was evaluated in predose and post-dose skin punch biopsies from 33 patients. On cycle
1 day 15, median percentage of baseline levels of Ki67 and pERK
ranged from 31% to 44% and 59% to 88%, respectively, across the
30 mg BID to 60 mg BID dose range; no post-dose biopsies were
available from the 80 mg dose group (Table 4). There were no
notable changes in pMEK relative to baseline.
Tumour tissue samples for pre-dose evaluation of mutations
and PTEN expression were collected from 85 patients. Twenty
patients (24%) had no mutations detected. Across all cohorts and
dose levels, the most common mutations were KRAS (33%), BRAF
(12%), KRAS þ PTEN (7%), KRAS þ PI3KCA (5%), and PTEN
(5%). The KRAS mutation was most common in the KRAS-mutant
579

BRITISH JOURNAL OF CANCER

Phase 1 binimetinib dose-escalation/expansion

Binimetinib concentration (ng ml–1)

10 000

Dose escalation - 30 mg BID (n=4)
Dose escalation - 45 mg BID (n=3)
Dose escalation - 60 mg BID (n=7)
Biliary cancer - 60 mg BID (n =5)
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Figure 1. Geometric mean (s.d.) plasma binimetinib concentrations on
cycle 1 day 15, intensive pharmacokinetic sampling scheme (semi-log
scale).

Binimetinib concentration (ng ml–1)

10 000

Biliary cancer-60 mg BID (n =17)
KRAS-mutant CRC-60 mg BID (n=4)
KRAS-mutant CRC-45 mg BID (n=20)
BRAF-mutant CRC-45 mg BID (n=12)

1000

colorectal cancer cohort, with 97% of these patients having a
confirmed KRAS mutation. The majority of such patients had only
mutations in KRAS (67% in 60 mg BID cohort; 72% in 45 mg BID
cohort) and not in other genes analysed. Similarly, the BRAF
mutation was most common in the BRAF-mutant colorectal cancer
cohort, with 93% of these patients having a confirmed BRAF
mutation and the majority of patients having only mutations in
BRAF (60%). In the biliary cancer cohort, 72% of patients had no
mutations detected. Of the 60 patients with tissue assessed for
expression of PTEN, 44 patients (73%) were PTEN positive
(including 16 patients in the biliary cancer cohort) and 16 patients
were PTEN null.
Response. Ninety-one patients (98%) were evaluable for response.
Of these, three objective responses (3%) were reported (one
complete response and two partial responses (PRs)), with
durations of 11.3 months, and 10.2 and 17.9 months, respectively.
All 3 of these patients had biliary cancer (3 of 30 patients with
biliary cancer (10%)); 1 patient was in the 80 mg BID cohort in the
dose-escalation phase, and the other 2 patients were in the biliary
cancer expansion phase 60 mg BID cohort. Of the three patients
who had objective responses, one tumour sample showed an NRAS
mutation (PR patient), whereas no mutations were detected for the
other two patients. An additional 33 patients (36%) had a best
response of stable disease, with a median duration of 3.94 months
(range, 0.92–11.53 months).
Progression-free survival and OS were estimated for patients in
the expansion phase cohorts. Median PFS/OS was 1.4/7.1 months
in the BRAF-mutant colorectal cancer cohort, 1.5/4.7 months in
the KRAS-mutant colorectal cancer 45 mg dose cohort, 3.5/9.1
months in the KRAS-mutant colorectal cancer 60 mg dose cohort,
and 2.1/4.8 months in the biliary cohort.

100

DISCUSSION
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1
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Nominal time (h)

Figure 2. Geometric mean (s.d.) plasma binimetinib concentrations on
cycle 1 day 15, limited pharmacokinetic sampling scheme (semi-log
scale).

The dose-escalation portion of this phase 1 study determined the
MTD of binimetinib to be 60 mg BID. However, because of ocular
toxicities and the need for dose modifications among the initial
patients treated in the expansion phase, the starting dose was
reduced to 45 mg BID for the remainder of the expansion phase
and is the recommended phase 2 dose for subsequent single-agent
clinical studies. The 45 mg BID dose was also identified as the
MTD/recommended phase 2 dose in a recent phase I study of
binimetinib monotherapy conducted in Japan in patients with

Table 3. Plasma pharmacokinetic parameters for cycle 1 day 1 and cycle 1 day 15 for the intensive pharmacokinetic sampling
scheme
Dose-escalation phase

Cycle
1

Day
1

Parameter
AUC0–8, h*ng ml  1a
Cmax, ng ml

 1a

tmax, hb
1

15

30 mg BID
(n ¼ 4)
1000 (34.0)

45 mg BID
(n ¼ 4)
964 (28.4)

60 mg BID
(n ¼ 7)
1710 (23.9)

Expansion phase
80 mg BID
(n ¼ 4)
2220 (78.9)

Biliary 60 mg BID
(n ¼ 7)
Total (N ¼ 26)
1090 (293)

327 (28.6)

241 (43.2)

545 (32.3)

687 (66.6)

365 (141)

1.51 (1.00–4.07)

2.53 (1.50–3.02)

1.00 (0.500–4.08)

2.02 (1.00–10.0)

1.50 (1.13–10.0)

1490 (NC)

AUC0-8, h*ng ml  1a

NA (NA)

1820 (14.4)

NA (NA)

Cmax, ng ml  1a

417 (39.9)

273 (64.7)

512 (30.8)

NA (NA)

594 (68.8)

NA (NA)

1.50 (NC)

1.17 (18.4)

NA (NA)

2.50 (NC)

2.00 (1.07–2.87)

3.00 (0.533–7.12)

NA (NA)

1.50 (1.00–7.02)

RAUCa
tmax, hb

1.50 (1.50–3.83)

3760 (NC)

NR
NR
1.50 (0.500–10.0)
NR
NR
1.44 (32.8)
1.50 (0.533–7.12)

Abbreviations: AUC ¼ area under the plasma concentration-time curve; AUC0–8 ¼ AUC from time 0 to 8 h; BID = twice daily; Cmax ¼ first maximum observed plasma concentration;
CV ¼ coefficient of variation; NA ¼ not applicable; NC ¼ not calculated; NR ¼ not reportable; RAUC ¼ accumulation ratios.
a
Geometric mean (% CV).
b
Median (minimum–maximum).
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Table 4. Skin expression of Ki67 and pERK at cycle 1 day 15
30 mg
BID
(n ¼ 4)

45 mg
BID
(n ¼ 22)

60 mg BID Total
(n ¼ 7)
(N ¼ 33)

Ki67

44 (25–56)

33 (6–300)

31 (17–100) 33 (6–300)

pERK

88 (50–100) 66 (38–189) 59 (29–72) 64 (29–189)

Median (range)
percent of baseline

Abbreviations: BID ¼ twice daily.

advanced solid tumours (Watanabe et al, 2016). Consistent with
the known class effects of MEK inhibition (Adjei et al, 2008; Rosen
et al, 2011; Infante et al, 2012), common AEs included rash,
diarrhoea, nausea, peripheral oedema, vomiting, fatigue, and ocular
events. Laboratory abnormalities included increases in CK and
liver function tests. The pharmacokinetic profile of binimetinib was
approximately dose proportional over the range of doses evaluated.
Pharmacodynamic studies demonstrated target inhibition, with
decreases in TNF-a observed in serum samples and decreases in
Ki67 and pERK levels observed in skin punch biopsy samples.
A number of MEK inhibitors have been evaluated in clinical
trials; to date, trametinib, cobimetinib, and binimetinib are the
only agents in this class to demonstrate efficacy in phase 3 trials of
melanoma (Flaherty et al, 2012; Larkin et al, 2014; Long et al, 2014;
Robert et al, 2015; Dummer et al, 2016). Trametinib is indicated in
the United States as a single agent and in combination with the
BRAF inhibitor dabrafenib for BRAFV600E- or BRAFV600Kmutant metastatic melanoma (MEKINIST, 2014). Cobimetinib is
indicated in the United States for unresectable or metastatic
melanoma with a BRAFV600E or BRAFV600K mutation, in
combination with vemurafenib (Lee et al, 2015). Binimetinib
showed clinical activity in a phase 2 study (NCT01320085),
yielding a 15% response rate in patients with advanced NRASmutant melanoma (Ascierto et al, 2013; Van Herpen et al, 2015).
In the subsequent phase 3 NEMO study (NCT01763164),
binimetinib met its primary endpoint, conferring significantly
longer PFS vs dacarbazine in patients with NRAS-mutant
melanoma (Dummer et al, 2016).
In tumour types other than melanoma, responses to MEK
inhibition have been less common. In the first-in-human trial of
trametinib, 21 patients had objective responses, only 4 of whom
were non-melanoma patients (NSCLC and pancreas cancer (2
patients each) NCT00687622) (Infante et al, 2012). In addition, no
objective responses to single-agent treatment were reported in nonmelanoma patients in phase 1 trials of the MEK inhibitors
selumetinib (NCT00085787) (Adjei et al, 2008), cobimetinib
(NCT00467779) (Rosen et al, 2011), or pimasertib (NCT00982865)
(Delord et al, 2010).
In the current trial, three patients with biliary cancer had an
objective response to binimetinib treatment. However, of these
three patients, two had no mutations identified and 1 had an NRAS
mutation, suggesting no correlation between mutation status and
objective response in this study. This is consistent with data
reported from a phase 2 trial of selumetinib in patients with
metastatic biliary cancer, in which three patients (12%) achieved an
objective response, none of whom had mutations in RAF or RAS
(Bekaii-Saab et al, 2011). Disappointingly, no responses to
binimetinib were observed in patients with colorectal cancer in
either the KRAS- or BRAF-mutant cohorts; this result is consistent
with other single-agent clinical studies of MEK inhibitors in
patients with colorectal cancer (Rinehart et al, 2004; Zimmer et al,
2014) and suggests combination therapy may be needed to treat
this tumour type.
In summary, binimetinib was safe and tolerable at 45 mg BID,
with preliminary anti-tumour activity demonstrated in patients
with biliary cancer. Additional characterisation of the response to
binimetinib in the biliary cancer expansion cohort in this study is
www.bjcancer.com | DOI:10.1038/bjc.2017.10
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underway (manuscript in preparation) and further evaluation of
binimetinib in combination with gemcitabine and cisplatin in a
phase 1 study (NCT01828034) is ongoing. A preliminary report
noted encouraging results, with six patients experiencing partial
responses and four experiencing stable disease among the 12
patients who participated in the study (Lowery et al, 2015).
Binimetinib is also undergoing evaluation as monotherapy and in
combination with targeted and cytotoxic chemotherapies in other
tumour types known to have MAPK pathway activation, including
melanoma, NSCLC, and pancreatic, colorectal, and thyroid
cancers. Combining binimetinib with other therapies is a
promising strategy to overcome or delay resistance that has been
observed with MEK inhibition. A phase 3 trial of binimetinib in
combination with the BRAF inhibitor encorafenib (LGX818) for
BRAFV600E-mutant metastatic melanoma is also ongoing
(NCT01909453).
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